Navigation Links
Cerecor Raises $22 Million Series A Financing
Date:4/4/2012

BALTIMORE, April 4, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, announced today that it has raised over US$22 million in an overallotment of its January 2012 Series A preferred stock financing. The offering, which was placed with accredited investors including members of Cerecor's Board of Directors, significantly exceeded the offering maximum of US$15 million.  Maxim Group, LLC of New York, NY acted as placement agent in connection with the offering.

(Logo: http://photos.prnewswire.com/prnh/20120404/PH82224LOGO )

"The completion of this financing is an important step in bringing our lead product, FP01 for the treatment of chronic and acute cough, to the market and to support our early preclinical efforts in cognition and schizophrenia. We are delighted by the enthusiastic response to our offering, as it confirms the quality of our Company, its product pipeline and our founding team," stated Blake M. Paterson, M.D., Co-founder & CEO of Cerecor.

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. www.cerecor.com  

For More Information, contact:
John Dierkes
Kennedy Advisors
john@kennedyadvice.com 
(410) 935-9334


'/>"/>
SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
4. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
5. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
6. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
7. Creabilis Raises €15M ($20M) in Series B Fundraising Round
8. SironRX Therapeutics Raises $3.4 Million Series A
9. PPTA Praises Legislation That Protects the Treatment of Rare Diseases
10. Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign
11. FireFly® Toothbrush Facebook Campaign Raises Funds for Smile Train
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):